Nooresh Mirani, technical analyst with AMSEC, and Vijay Chopra, head-advisory with Fullerton Securities, feel that investors should book their profits once the upmove in Wockhardt resumes, keeping a target of Rs 1,800-2,000. Nooresh Mirani feels investors should be a little cautious given the huge upmove the stock has seen over the last one year. Mr. Chopra feels that the company has managed to restructure its debt very well and has some well established brands under its belt and is a pharma stock with reasonable valuations and strong fundamentals.